Mar 01, 2021 / 04:40PM GMT
Doug Schenkel - Cowen and Company, LLC, Research Division - MD & Senior Research Analyst
All right. Good morning, everybody, and welcome back. I'm Doug Schenkel from the Cowen life science and diagnostic tools team. It's our pleasure to welcome Rainer Blair to the 41st Annual Cowen and Company Health Care Conference.
For those of you who are maybe a little bit new to the Danaher story, just as way of background, Rainer took over as President and CEO of Danaher in September of last year, though he's been at Danaher for over a decade. He played an instrumental role in developing the company's highly successful Life Sciences platform, and was a key figure behind the major acquisitions of both Pall and Cytiva.
Our goal for the next 30 minutes is to really try to tackle 3 things. I mean this is an ambitious agenda, but we'll start by talking about the company's response to COVID-19. And more importantly, at least in our view, as we sit here today, the outlook for that part of the business, and hopefully, a post-COVID-19 world. Secondly, to just break down and go back to breaking down 2021
Danaher Corp at Cowen Healthcare Conference (Virtual) Transcript
Jan 22, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers